216 related articles for article (PubMed ID: 28802905)
1. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.
Garcia S; Bisen A; Yan J; Xie XJ; Ramalingam S; Schiller JH; Johnson DH; Gerber DE
J Thorac Oncol; 2017 Oct; 12(10):1489-1495. PubMed ID: 28802905
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
Gerber DE; Singh H; Larkins E; Ferris A; Forde PM; Selig W; Basu Roy U
JAMA Oncol; 2022 Sep; 8(9):1333-1339. PubMed ID: 35925576
[TBL] [Abstract][Full Text] [Related]
4. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group.
Spira AI; Stewart MD; Jones S; Chang E; Fielding A; Richie N; Wood LS; Thompson MA; Jones L; Nair A; Mahal BA; Gerber DE
Clin Cancer Res; 2021 May; 27(9):2416-2423. PubMed ID: 33563636
[TBL] [Abstract][Full Text] [Related]
5. Increasing the efficiency of trial-patient matching: automated clinical trial eligibility pre-screening for pediatric oncology patients.
Ni Y; Wright J; Perentesis J; Lingren T; Deleger L; Kaiser M; Kohane I; Solti I
BMC Med Inform Decis Mak; 2015 Apr; 15():28. PubMed ID: 25881112
[TBL] [Abstract][Full Text] [Related]
6. Impact of prior cancer on eligibility for lung cancer clinical trials.
Gerber DE; Laccetti AL; Xuan L; Halm EA; Pruitt SL
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25253615
[TBL] [Abstract][Full Text] [Related]
7. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.
Srikanthan A; Vera-Badillo F; Ethier J; Goldstein R; Templeton AJ; Ocana A; Seruga B; Amir E
Cancer Treat Rev; 2016 Feb; 43():67-73. PubMed ID: 26827694
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
9. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
10. Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual.
Wang YQ; Lv JW; Tang LL; Du XJ; Chen L; Li WF; Liu X; Guo Y; Lin AH; Mao YP; Sun Y; Chen YP; Ma J
Oral Oncol; 2019 Mar; 90():23-29. PubMed ID: 30846172
[TBL] [Abstract][Full Text] [Related]
11. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.
Uldrick TS; Ison G; Rudek MA; Noy A; Schwartz K; Bruinooge S; Schenkel C; Miller B; Dunleavy K; Wang J; Zeldis J; Little RF
J Clin Oncol; 2017 Nov; 35(33):3774-3780. PubMed ID: 28968173
[TBL] [Abstract][Full Text] [Related]
12. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
Kim ES; Bruinooge SS; Roberts S; Ison G; Lin NU; Gore L; Uldrick TS; Lichtman SM; Roach N; Beaver JA; Sridhara R; Hesketh PJ; Denicoff AM; Garrett-Mayer E; Rubin E; Multani P; Prowell TM; Schenkel C; Kozak M; Allen J; Sigal E; Schilsky RL
J Clin Oncol; 2017 Nov; 35(33):3737-3744. PubMed ID: 28968170
[TBL] [Abstract][Full Text] [Related]
13. Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.
Forde PM; Bonomi P; Shaw A; Blumenthal GM; Ferris A; Patel C; Melemed A; Basu Roy U; Ramamoorthy A; Liu Q; Burns T; Gainor JF; Lovly C; Piotrowska Z; Lehman J; Selig W
Clin Lung Cancer; 2020 Jul; 21(4):295-307. PubMed ID: 32201247
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility Screening.
Marcath LA; Coe TD; Shakeel F; Reynolds E; Bayuk M; Haas S; Redman BG; Wong SF; Hertz DL
J Patient Saf; 2021 Jan; 17(1):e28-e34. PubMed ID: 33003175
[TBL] [Abstract][Full Text] [Related]
16. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
Osarogiagbon RU; Vega DM; Fashoyin-Aje L; Wedam S; Ison G; Atienza S; De Porre P; Biswas T; Holloway JN; Hong DS; Wempe MM; Schilsky RL; Kim ES; Wade JL
Clin Cancer Res; 2021 May; 27(9):2408-2415. PubMed ID: 33563637
[TBL] [Abstract][Full Text] [Related]
17. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials.
Horn L; Keedy VL; Campbell N; Garcia G; Hayes A; Spencer B; Carbone DP; Sandler A; Johnson DH
Clin Lung Cancer; 2013 Jan; 14(1):14-8. PubMed ID: 22591607
[TBL] [Abstract][Full Text] [Related]
18. Artificial Intelligence Tool for Optimizing Eligibility Screening for Clinical Trials in a Large Community Cancer Center.
Beck JT; Rammage M; Jackson GP; Preininger AM; Dankwa-Mullan I; Roebuck MC; Torres A; Holtzen H; Coverdill SE; Williamson MP; Chau Q; Rhee K; Vinegra M
JCO Clin Cancer Inform; 2020 Jan; 4():50-59. PubMed ID: 31977254
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials.
Logan JK; Tang C; Liao Z; Lee JJ; Heymach JV; Swisher SG; Welsh JW; Zhang J; Lin SH; Gomez DR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):770-777. PubMed ID: 28244413
[TBL] [Abstract][Full Text] [Related]
20. QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.
Le T; Yang H; Rashdan S; Link MS; Zaha VG; Alvarez C; Gerber DE
Clin Lung Cancer; 2020 Jan; 21(1):21-27.e5. PubMed ID: 31780402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
